secwatch.observer — SEC 8-K summary
======================================

Issuer:     Upstream Bio, Inc. (UPB)
CIK:        0002022626
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001193125-26-045649
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Upstream Bio reports preliminary cash of $341.5M; Phase 2 VALIANT top-line data released
--------------------------------------------------------------------------------

- Preliminary unaudited cash, cash equivalents and short-term investments of $341.5M as of Dec 31, 2025.
- Top-line results from Phase 2 VALIANT trial of verekitug in severe asthma presented in webcast; details in investor presentation.
- Year-end 2025 financial close not yet completed; full results to be included in Form 10-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022626/000119312526045649/0001193125-26-045649-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022626/000119312526045649/d103888d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-045649

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer